NICE Recommends Takhzyro for Angioedema in Patients 12 and Older

Takeda’s Takhzyro (lanadelumab) subcutaneous injection received the green light from the UK’s National Institute for Health and Care Excellence for preventing recurring attacks of hereditary angioedema in patients 12 years and older.

The rare genetic disorder causes recurring attacks of swelling in various areas of the body, including the face, feet, genitals, abdomen, hands and throat. The swelling can be life-threatening if the patient’s airway is affected.

As part of the approval, patients must be eligible for preventive C1-esterase inhibitor treatment and must use the lowest dosing frequency.